Adaptimmune Therapeutics (ADAP) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

ADAP Stock Forecast

Adaptimmune Therapeutics stock forecast is as follows: an average price target of $2.83 (represents a 325.76% upside from ADAP’s last price of $0.66) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.

ADAP Price Target

The average price target for Adaptimmune Therapeutics (ADAP) is $2.83 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $4.00 to $1.00. This represents a potential 325.76% upside from ADAP's last price of $0.66.

ADAP Analyst Ratings

Buy

According to 5 Wall Street analysts, Adaptimmune Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for ADAP stock is 0 'Strong Buy' (0.00%), 3 'Buy' (60.00%), 1 'Hold' (20.00%), 1 'Sell' (20.00%), and 0 'Strong Sell' (0.00%).

Adaptimmune Therapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Jul 30, 2024	Arthur He	H.C. Wainwright	$4.00	$1.37	191.97%	501.78%
May 30, 2024	George Farmer	Scotiabank	$3.15	$1.01	211.88%	373.90%
May 17, 2024	Graig Suvannavejh	Mizuho Securities	$3.00	$1.20	150.00%	351.33%
May 16, 2024	Peter Lawson	Barclays	$1.00	$1.20	-16.67%	50.44%
Nov 14, 2022	-	Wells Fargo	$3.00	$2.51	19.52%	351.33%

Row per page

Go to

The latest Adaptimmune Therapeutics stock forecast, released on Jul 30, 2024 by Arthur He from H.C. Wainwright, set a price target of $4.00, which represents a 191.97% increase from the stock price at the time of the forecast ($1.37), and a 501.78% increase from ADAP last price ($0.66).

Adaptimmune Therapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	4
Avg Price Target	-	-	$2.79
Last Closing Price	$0.66	$0.66	$0.66
Upside/Downside	-100.00%	-100.00%	319.74%

In the current month, the average price target of Adaptimmune Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Adaptimmune Therapeutics's last price of $0.66. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Aug 05, 2024	Scotiabank	Sector Outperform	Sector Outperform	Hold
Aug 05, 2024	H.C. Wainwright	Underperform	Underperform	Hold
Jul 30, 2024	H.C. Wainwright	-	Buy	Initialise
May 31, 2024	Wells Fargo	Equal-Weight	Equal-Weight	Hold
May 30, 2024	Scotiabank	-	Outperform	Initialise
May 16, 2024	Barclays	Underweight	Underweight	Hold
Jan 03, 2023	Guggenheim	-	Buy	Upgrade
Nov 09, 2022	Bank of America Securities	-	Buy	Upgrade
Nov 09, 2022	Mizuho Securities	-	Buy	Upgrade

Row per page

Go to

Adaptimmune Therapeutics's last stock rating was published by Scotiabank on Aug 05, 2024. The company gave ADAP a "Sector Outperform" rating, the same as its previous rate.

Adaptimmune Therapeutics Financial Forecast

Adaptimmune Therapeutics Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	$231.00K	$7.32M	$5.13M	$47.60M	$11.03M	$7.01M	$5.54M	$3.58M	$1.42M	$1.20M	$3.10M	$434.00K	$1.50M	$1.19M	$502.00K	$761.00K	$728.00K	$237.00K
Avg Forecast	$170.98M	$145.85M	$124.42M	$106.14M	$13.25M	$9.78M	$7.42M	$5.75M	$7.75M	$18.96M	$40.47M	$9.88M	$25.96M	$7.97M	$6.13M	$5.15M	$3.83M	$6.93M	$6.57M	$3.50M	$4.50M	$1.53M	$1.40M	$1.83M	$1.80M	$1.02M	$7.94M	$23.29M	$1.30M	$1.48M
High Forecast	$298.31M	$254.48M	$217.08M	$185.18M	$23.12M	$17.05M	$12.95M	$10.03M	$12.00M	$19.16M	$70.61M	$17.24M	$45.29M	$13.91M	$10.69M	$8.99M	$6.69M	$6.93M	$6.57M	$3.50M	$4.50M	$1.53M	$1.40M	$1.83M	$1.80M	$1.02M	$7.94M	$23.29M	$1.30M	$1.48M
Low Forecast	$94.02M	$80.20M	$68.42M	$58.36M	$7.29M	$5.37M	$4.08M	$3.16M	$4.28M	$18.77M	$22.25M	$5.43M	$14.27M	$4.38M	$3.37M	$2.83M	$2.11M	$6.93M	$6.57M	$3.50M	$4.50M	$1.53M	$1.40M	$1.83M	$1.80M	$1.02M	$7.94M	$23.29M	$1.30M	$1.48M
# Analysts	1	1	1	1	1	1	1	2	5	4	1	1	3	1	1	1	1	1	1	1	1	1	1	1	10	16	8	11	7	11
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.01%	0.92%	0.84%	9.24%	2.88%	1.01%	0.84%	1.02%	0.31%	0.78%	2.21%	0.24%	0.83%	1.17%	0.06%	0.03%	0.56%	0.16%

Adaptimmune Therapeutics's average Quarter revenue forecast for Mar 24 based on 1 analysts is $9.88M, with a low forecast of $5.43M, and a high forecast of $17.24M. ADAP's average Quarter revenue forecast represents a 4177.06% increase compared to the company's last Quarter revenue of $231.00K (Dec 23).

Adaptimmune Therapeutics EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	2	5	4	1	1	3	1	1	1	1	1	1	1	1	1	1	1	10	16	8	11	7	11
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	$-47.26M	$-46.29M	$-64.83M	$3.50M	$-27.24M	$-41.50M	$-42.20M	$-48.39M	$-36.41M	$-40.74M	$-37.55M	$-36.03M	$-34.84M	$-33.59M	$-27.70M	$-26.21M	$-27.18M	$-37.27M
Avg Forecast	$-170.98M	$-145.85M	$-124.42M	$-106.14M	$-13.25M	$-9.78M	$-7.42M	$-5.75M	$-7.75M	$-18.96M	$-40.47M	$-26.54M	$-25.96M	$-7.97M	$-6.13M	$-28.38M	$-31.16M	$-6.93M	$-6.57M	$-30.35M	$-4.50M	$-1.53M	$-1.40M	$-37.47M	$-1.80M	$-1.02M	$-7.94M	$-25.36M	$-1.30M	$-1.48M
High Forecast	$-94.02M	$-80.20M	$-68.42M	$-58.36M	$-7.29M	$-5.37M	$-4.08M	$-3.16M	$-4.28M	$-18.77M	$-22.25M	$-21.23M	$-14.27M	$-4.38M	$-3.37M	$-22.70M	$-24.92M	$-6.93M	$-6.57M	$-24.28M	$-4.50M	$-1.53M	$-1.40M	$-29.98M	$-1.80M	$-1.02M	$-7.94M	$-20.29M	$-1.30M	$-1.48M
Low Forecast	$-298.31M	$-254.48M	$-217.08M	$-185.18M	$-23.12M	$-17.05M	$-12.95M	$-10.03M	$-12.00M	$-19.16M	$-70.61M	$-31.84M	$-45.29M	$-13.91M	$-10.69M	$-34.06M	$-37.39M	$-6.93M	$-6.57M	$-36.42M	$-4.50M	$-1.53M	$-1.40M	$-44.96M	$-1.80M	$-1.02M	$-7.94M	$-30.43M	$-1.30M	$-1.48M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	1.82%	5.81%	10.58%	-0.12%	0.87%	5.99%	6.42%	1.59%	8.09%	26.57%	26.82%	0.96%	19.35%	33.04%	3.49%	1.03%	20.91%	25.18%

1 analysts predict ADAP's average Quarter EBITDA for Jun 23 to be $-6.13M, with a high of $-3.37M and a low of $-10.69M. This is -275.05% lower than Adaptimmune Therapeutics's previous annual EBITDA (Mar 23) of $3.50M.

Adaptimmune Therapeutics Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	2	5	4	1	1	3	1	1	1	1	1	1	1	1	1	1	1	10	16	8	11	7	11
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	$-47.92M	$-45.60M	$-21.39M	$1.04M	$-29.25M	$-41.42M	$-44.52M	$-50.27M	$-38.86M	$-42.40M	$-39.07M	$-37.76M	$-36.61M	$-35.43M	$-29.88M	$-28.17M	$-29.36M	$-39.30M
Avg Forecast	$-19.34M	$-21.38M	$-25.45M	$-27.52M	$-22.21M	$-24.35M	$-27.64M	$-30.03M	$-7.17M	$-2.42M	$-11.21M	$-27.96M	$-42.20M	$-49.62M	$-37.12M	$-29.91M	$-32.74M	$-64.97M	$-75.36M	$-31.99M	$31.70M	$-68.55M	$-9.74M	$-39.27M	$-60.63M	$-65.83M	$-61.50M	$-29.29M	$-88.35M	$-79.26M
High Forecast	$-8.02M	$-8.87M	$-10.56M	$-11.42M	$-9.21M	$-10.10M	$-11.47M	$-12.46M	$-2.56M	$-1.00M	$-4.65M	$-22.37M	$-24.62M	$-20.58M	$-15.40M	$-23.93M	$-26.20M	$-64.97M	$-75.36M	$-25.59M	$31.70M	$-68.55M	$-9.74M	$-31.42M	$-60.63M	$-65.83M	$-61.50M	$-23.43M	$-88.35M	$-79.26M
Low Forecast	$-38.06M	$-42.08M	$-50.09M	$-54.16M	$-43.71M	$-47.93M	$-54.41M	$-59.11M	$-10.24M	$-4.76M	$-22.06M	$-33.56M	$-56.27M	$-97.66M	$-73.07M	$-35.89M	$-39.29M	$-64.97M	$-75.36M	$-38.38M	$31.70M	$-68.55M	$-9.74M	$-47.13M	$-60.63M	$-65.83M	$-61.50M	$-35.15M	$-88.35M	$-79.26M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	1.14%	0.92%	0.58%	-0.03%	0.89%	0.64%	0.59%	1.57%	-1.23%	0.62%	4.01%	0.96%	0.60%	0.54%	0.49%	0.96%	0.33%	0.50%

Adaptimmune Therapeutics's average Quarter net income forecast for Jun 23 is $-37.12M, with a range of $-73.07M to $-15.40M. ADAP's average Quarter net income forecast represents a -3683.48% decrease compared to the company's last Quarter net income of $1.04M (Mar 23).

Adaptimmune Therapeutics SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	2	5	4	1	1	3	1	1	1	1	1	1	1	1	1	1	1	10	16	8	11	7	11
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	$16.88M	$16.16M	$20.07M	$20.40M	$15.22M	$16.82M	$16.89M	$16.80M	$15.48M	$15.17M	$14.99M	$13.82M	$13.24M	$13.00M	$10.29M	$9.26M	$10.73M	$10.74M
Avg Forecast	$2.16B	$1.84B	$1.57B	$1.34B	$167.26M	$123.39M	$93.73M	$72.58M	$97.87M	$239.39M	$510.87M	$9.35M	$327.70M	$100.63M	$77.36M	$65.01M	$48.39M	$86.82M	$82.35M	$43.86M	$56.39M	$19.21M	$17.54M	$22.97M	$22.56M	$12.74M	$99.53M	$9.63M	$16.29M	$18.55M
High Forecast	$3.77B	$3.21B	$2.74B	$2.34B	$291.82M	$215.29M	$163.53M	$126.64M	$151.54M	$241.87M	$891.33M	$11.22M	$571.75M	$175.57M	$134.98M	$113.43M	$84.43M	$86.82M	$82.35M	$43.86M	$56.39M	$19.21M	$17.54M	$22.97M	$22.56M	$12.74M	$99.53M	$11.56M	$16.29M	$18.55M
Low Forecast	$1.19B	$1.01B	$863.63M	$736.73M	$91.97M	$67.85M	$51.54M	$39.91M	$54.01M	$236.90M	$280.91M	$7.48M	$180.19M	$55.33M	$42.54M	$35.75M	$26.61M	$86.82M	$82.35M	$43.86M	$56.39M	$19.21M	$17.54M	$22.97M	$22.56M	$12.74M	$99.53M	$7.71M	$16.29M	$18.55M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.05%	0.16%	0.26%	0.31%	0.31%	0.19%	0.21%	0.38%	0.27%	0.79%	0.85%	0.60%	0.59%	1.02%	0.10%	0.96%	0.66%	0.58%

Adaptimmune Therapeutics's average Quarter SG&A projection for Mar 24 is $9.35M, based on 1 Wall Street analysts, with a range of $7.48M to $11.22M. The forecast indicates a -44.61% fall compared to ADAP last annual SG&A of $16.88M (Dec 23).

Adaptimmune Therapeutics EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	2	5	4	1	1	3	1	1	1	1	1	1	1	1	1	1	1	10	16	8	11	7	11
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	$-0.34	$-0.12	$0.01	$-0.18	$-0.25	$-0.28	$-0.32	$-0.25	$-0.27	$-0.25	$-0.24	$-0.24	$-0.23	$-0.22	$-0.23	$-0.28	$-0.37
Avg Forecast	$-0.08	$-0.08	$-0.10	$-0.11	$-0.09	$-0.10	$-0.11	$-0.12	$-0.03	$-0.01	$-0.04	$-0.15	$-0.17	$-0.19	$-0.15	$-0.19	$-0.24	$-0.25	$-0.29	$-0.25	$0.12	$-0.26	$-0.04	$-0.04	$-0.23	$-0.25	$-0.24	$-0.25	$-0.34	$-0.30
High Forecast	$-0.03	$-0.03	$-0.04	$-0.04	$-0.04	$-0.04	$-0.04	$-0.05	$-0.01	$-0.00	$-0.02	$-0.06	$-0.10	$-0.08	$-0.06	$-0.08	$-0.10	$-0.25	$-0.29	$-0.25	$0.12	$-0.26	$-0.04	$-0.04	$-0.23	$-0.25	$-0.24	$-0.25	$-0.34	$-0.30
Low Forecast	$-0.15	$-0.16	$-0.20	$-0.21	$-0.17	$-0.19	$-0.21	$-0.23	$-0.04	$-0.02	$-0.09	$-0.30	$-0.22	$-0.38	$-0.29	$-0.37	$-0.48	$-0.25	$-0.29	$-0.25	$0.12	$-0.26	$-0.04	$-0.04	$-0.23	$-0.25	$-0.24	$-0.25	$-0.34	$-0.30
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	1.75%	0.83%	-0.03%	0.73%	1.00%	0.97%	1.26%	-2.05%	1.02%	6.67%	6.48%	1.03%	0.91%	0.93%	0.91%	0.82%	1.21%

According to 1 Wall Street analysts, Adaptimmune Therapeutics's projected average Quarter EPS for Jun 23 is $-0.15, with a low estimate of $-0.29 and a high estimate of $-0.06. This represents a -2403.97% decrease compared to ADAP previous annual EPS of $0.01 (Mar 23).

Adaptimmune Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
ACET	Adicet Bio	$0.97	$32.50	3250.52%	Buy
NKTX	Nkarta	$2.50	$21.60	764.00%	Buy
SGMO	Sangamo Therapeutics	$1.95	$12.00	515.38%	Buy
BDTX	Black Diamond Therapeutics	$2.43	$14.75	507.00%	Buy
PDSB	PDS Bio	$2.03	$9.00	343.35%	Buy
ADAP	Adaptimmune Therapeutics	$0.66	$2.83	328.79%	Buy
PLRX	Pliant Therapeutics	$12.73	$39.71	211.94%	Buy
FIXX	Q32 Bio	$0.93	$2.70	190.32%	Buy
AFMD	Affimed	$2.72	$7.50	175.74%	Buy
STOK	Stoke Therapeutics	$11.31	$30.60	170.56%	Buy
LPTX	Leap Therapeutics	$2.59	$5.50	112.36%	Buy
MREO	Mereo BioPharma Group	$3.58	$6.75	88.55%	Buy
CRVS	Corvus Pharmaceuticals	$8.24	$10.67	29.49%	Buy
AGIO	Agios Pharmaceuticals	$54.62	$48.00	-12.12%	Buy

ADAP Forecast FAQ

Is Adaptimmune Therapeutics a good buy?

Yes, according to 5 Wall Street analysts, Adaptimmune Therapeutics (ADAP) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 60.00% of ADAP's total ratings.

What is ADAP's price target?

Adaptimmune Therapeutics (ADAP) average price target is $2.83 with a range of $1 to $4, implying a 325.76% from its last price of $0.665. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Adaptimmune Therapeutics stock go up soon?

According to Wall Street analysts' prediction for ADAP stock, the company can go up by 325.76% (from the last price of $0.665 to the average price target of $2.83), up by 501.78% based on the highest stock price target, and up by 50.44% based on the lowest stock price target.

Can Adaptimmune Therapeutics stock reach $1?

ADAP's average twelve months analyst stock price target of $2.83 supports the claim that Adaptimmune Therapeutics can reach $1 in the near future.

What are Adaptimmune Therapeutics's analysts' financial forecasts?

Adaptimmune Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $36.2M (high $63.16M, low $19.91M), average EBITDA is $-36.2M (high $-19.905M, low $-63.159M), average net income is $-104M (high $-43.242M, low $-205M), average SG&A $456.97M (high $797.28M, low $251.27M), and average EPS is $-0.408 (high $-0.169, low $-0.802). ADAP's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $547.39M (high $955.05M, low $300.99M), average EBITDA is $-547M (high $-301M, low $-955M), average net income is $-93.688M (high $-38.865M, low $-184M), average SG&A $6.91B (high $12.06B, low $3.8B), and average EPS is $-0.366 (high $-0.152, low $-0.721).

Did the ADAP's actual financial results beat the analysts' financial forecasts?

Based on Adaptimmune Therapeutics's last annual report (Dec 2023), the company's revenue was $60.28M, beating the average analysts forecast of $45.21M by 33.34%. Apple's EBITDA was $-115M, beating the average prediction of $-68.44M by 68.33%. The company's net income was $-114M, missing the average estimation of $-159M by -28.32%. Apple's SG&A was $73.51M, missing the average forecast of $570.7M by -87.12%. Lastly, the company's EPS was $-0.0001, missing the average prediction of $-0.69 by -99.99%. In terms of the last quarterly report (Dec 2023), Adaptimmune Therapeutics's revenue was $231K, missing the average analysts' forecast of $25.96M by -99.11%. The company's EBITDA was $-47.261M, beating the average prediction of $-25.96M by 82.05%. Adaptimmune Therapeutics's net income was $-47.917M, beating the average estimation of $-42.202M by 13.54%. The company's SG&A was $16.88M, missing the average forecast of $327.7M by -94.85%. Lastly, the company's EPS was $0, missing the average prediction of $-0.165 by -100.00%